Keep Current with the Latest in Cell Biology Research

Pfizer’s Abrocitinib Receives Positive CHMP Opinion for the Treatment of Adults with Moderate to Severe Atopic Dermatitis

Pfizer, Inc. announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the 100 mg and 200 mg doses of abrocitinib, an oral, once-daily, Janus kinase 1 inhibitor, for marketing authorization to treat moderate to severe atopic dermatitis in adults who are candidates for systemic therapy.
[Pfizer, Inc.]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (Ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis

Bristol Myers Squibb announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Zeposia for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.
[Bristol Myers Squibb]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Mechanisms of Abemaciclib, a CDK4/6 Inhibitor, Induced Apoptotic Cell Death in Prostate Cancer Cells In Vitro

Researchers analyzed in vitro cytotoxic and apoptotic effects of abemaciclib on metastatic castration-resistant prostate cancer androgen receptor negative PC-3 and AR mutant LNCaP prostate cancer cells.
[Translational Oncology]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Dual Akt and Bcl-2 Inhibition Induces Cell-Type Specific Modulation of Apoptotic and Autophagic Signaling in Castration Resistant Prostate Cancer Cell Lines

The authors elucidated the modulation patterns between apoptosis and autophagy following dual inhibition by Akt inhibitor erufosine and Bcl-2 inhibitor ABT-737 in castration-resistant prostate cancer cell lines, PC-3 (Bax+) and DU-145 (Bax−).
[Molecular Biology Reports]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Supraphysiological Testosterone Induces Ferroptosis and Activates Immune Pathways through Nucleophagy in Prostate Cancer

Investigators reported that supraphysiological levels of testosterone (SupraT) activated cytoplasmic nucleic acid sensors and induced growth inhibition of SupraT-sensitive prostate cancer cells.
[Cancer Research]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Targeting KDM6A Suppresses SREBP1c-Dependent Lipid Metabolism and Prostate Tumorigenesis

Scientists reported that specific homozygous deletion of KDM6A in the adult mouse prostate epithelium strongly inhibited tumor progression initiated by the homozygous loss of PTEN. Mechanistically, KDM6A promoted prostate tumorigenesis and lipid metabolism by binding to the SREBP1c promoter which resulted in increased SREBP1c transcription.
[Cancer Research]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Bortezomib Potentiates Antitumor Activity of Mitoxantrone through Dampening Wnt/β-Catenin Signal Pathway in Prostate Cancer Cells

Researchers determined the anticancer effects of a combination of bortezomib and mitoxantrone by apoptosis and proliferation assay in vivo and in vitro.
[BMC Cancer]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Reorganization of the 3D Genome Pinpoints Non-coding Drivers of Primary Prostate Tumors

The authors investigated the molecular mech­­anisms of long non‑coding RNA small nucleolar RNA host gene 16 in the proliferation and metastasis of prostate cancer cells.
[Molecular Medicine Reports]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Abstract
Bookmark

No account yet? Register

Share

Current Status of Organoid Culture in Urological Malignancy

The authors summarize the development and applications of three-dimensional organoid cultures in urological cancers, mainly focusing on prostate, urinary bladder and kidney cancers, and assess the future prospects of this model.
[International Journal of Urology]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share

Tricol Biomedical Receives NIH Phase IIB Grant to Continue Development of its Hemostatic Device for the Prostate

Tricol Biomedical, Inc. has received an $853,585 grant from the National Institute Of Diabetes And Digestive And Kidney Diseases. This Phase IIB grant will support final development of Tricol’s proprietary hemostatic device to address bleeding in prostate-related procedures for treatment of both benign and malignant prostate conditions.
[Tricol Biomedical, Inc. (GlobeNewswire, Inc.)]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Press Release
Bookmark

No account yet? Register

Share

Novel Scaffold Based Graphene Oxide Doped Electrospun Iota Carrageenan/Polyvinyl Alcohol for Wound Healing and Pathogen Reduction: In-Vitro and In-Vivo Study

Scientists worked with electrospun nanofiber scaffold named that was composed of polyvinyl alcohol/iota carrageenan and doped with partially reduced graphene oxide that was successfully synthesized for wound healing and skin repair.
[Scientific Reports]
[zotpress userid=’6445218′ items=’AAAAAAAA’ style=’apa’ cite=’yes’]
Full Article
Bookmark

No account yet? Register

Share
Share